Human respiratory syncytial virus (RSV) is a major cause of respiratory infection in children and in the elderly. The RSV fusion (F) glycoprotein has long been recognized as a vaccine candidate as it elicits cytotoxic T-lymphocyte (CTL) and antibody responses. Two murine H-2K d -restricted CTL epitopes (F85-93 and F92-106) are known in the F protein of the A2 strain of RSV. F-specific CTL lines using BCH4 fibroblasts that are persistently infected with the Long strain of human RSV as stimulators were generated, and it was found that in this strain only the F85-93 epitope is conserved. Motif based epitope prediction programs and an F2 chain deleted F protein encoded in a recombinant vaccinia virus enabled identification of a new epitope in the Long strain, F249-258, which is presented by K d as a 9-mer (TYMLTNSEL) or a 10-mer (TYMLTNSELL) peptide. The results suggest that the 10-mer might be a naturally processed endogenous K d ligand. The CD8 + T-lymphocyte responses to epitopes F85-93 and F249-258 present in the F protein of RSV Long were found to be strongly skewed to F85-93 in in vitro multispecific CTL lines and in vivo during a secondary response to a recombinant vaccinia virus that expresses the entire F protein. However, no hierarchy in CD8 + T-lymphocyte responses to F85-93 and F249-258 epitopes was observed in vivo during a primary response.
INTRODUCTION
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection in infants and young children (Collins et al., 2001) , affecting also immunocompromised patients and the elderly. Reinfection is common and currently no effective vaccine is available (Simoes, 1999) .
Immune mechanisms involved in RSV disease and protection are not well understood. Protection is mediated mainly by neutralizing antibodies directed to the two virion surface glycoproteins, while clearance of virus-infected cells requires CD8 + T lymphocytes. Studies in the mouse model of human RSV have shown that CD8 + T lymphocytes play a role both in lung pathology and viral clearance (Cannon et al., 1988; Graham et al., 1991) . CD8
+ T lymphocytes are thought to regulate differentiation and activation of Th2 CD4
+ T lymphocytes, which mediate lung pathology by recruiting eosinophils into the lungs during RSV infection (Srikiatkhachorn & Braciale, 1997) . On the other hand, CD8
+ T lymphocytes specific for the matrix 2 (M2) M2 82-92 epitope have been found to be the sole mediators of resistance to RSV infection in BALB/c mice infected with a recombinant vaccinia virus (rVV) expressing the M2 protein of RSV (Kulkarni et al., 1995) . Further studies found that RSV infection altered CD8
+ effector activity and memory T lymphocytes selectively in the lungs (Chang & Braciale, 2002; Chang et al., 2001) . This RSV-induced immune dysregulation of virus-specific CD8 + T lymphocytes has been suggested as a possible mechanism for the absence of durable long-lived immunity to RSV infection (Chang & Braciale, 2002) .
The fusion (F) protein of RSV, one of the two major surface glycoproteins in the virion, has long been recognized as a major vaccine candidate as it is an important target antigen for virus-specific cytotoxic T lymphocytes (CTL) (Pemberton et al., 1987) and neutralizing antibodies (Olmsted et al., 1986) . Monoclonal antibodies to the F glycoprotein, which is highly conserved among the two antigenic groups of human RSV, passively protect against human RSV challenge in the mouse (Taylor et al., 1984) and reduce the severity of disease in premature and newborn babies (The IMpact-RSV Study Group, 1998) . Furthermore, immunization of mice with rVV (Olmsted et al., 1986; Stott et al., 1987) or plasmid DNA encoding the F protein (Bembridge et al., 2000; Li et al., 1998) , which induce Fspecific antibodies and CTL, confers protection against challenge with RSV of either antigenic group.
Human RSV F glycoprotein is synthesized as a 574 aa F0 precursor that is processed at two cleavage residues (109 and 136) by furin-like proteases (González-Reyes et al., 2001; Zimmer et al., 2001) . Cleavage yields two chains that remain linked by a disulfide bond. The larger carboxyterminal F1 chain hosts the fusion peptide, the transmembrane region and several neutralizing antibody antigenic sites . The amino-terminal signal sequence is followed by the F2 chain, which has recently been found to be responsible for RSV host-cell specificity suggesting it is the binding partner for specific RSV entry receptors (Schlender et al., 2003) . Furthermore, two murine H-2K d -restricted epitopes recognized by CTL, F85-93 and F92-106, have been identified in the F2 chain of the A2 strain of human RSV (Chang et al., 2001; Jiang et al., 2002) .
In this study, we used a novel approach to generate RSVspecific CTL lines by stimulating primed mouse splenocytes with the BCH4 fibroblast cell line that is persistently infected with the Long strain of RSV (Fernie et al., 1981) . We found that the F92-106 epitope is not present in RSV Long whereas the F85-93 epitope is conserved between strains. We searched for CTL epitopes in the F1 chain by using CTL lines, epitope prediction programs and an rVV encoding a mutant F protein, in which the F2 chain was deleted. A novel H-2K d -restricted epitope, F249-258, was identified. No hierarchy in CD8 + T-lymphocyte responses to F85-93 and F249-258 epitopes was found in vivo during a primary response to an rVV expressing the full-length F glycoprotein. In contrast, F249-258 was found subdominant with respect to F85-93 in in vivo memory and secondary responses, and in CTL lines generated in vitro.
METHODS
Viruses. Human RSV Long was grown in HEp-2 monolayers and purified from culture supernatants as described previously (García-Barreno et al., 1988) .
Construction of recombinant vvF containing the F gene of RSV Long (VRBF) has been described (Bembridge et al., 1998) . An rVV expressing an F protein with aa 34-128 (both included) deleted, vvF-DF2, was obtained as follows: plasmid LF1, containing a cDNA copy of the entire F protein gene of the Long strain (Cristina et al., 1990) , was mutagenized to introduce a restriction site recognized by BbsI (nt 106, Long sequence; Ló pez et al., 1988) and AflII (nt 397), using the Quick-Change site-directed mutagenesis kit (Stratagene) and appropriate oligonucleotides. The resulting plasmid was digested with BbsI and AflII, treated with Klenow polymerase to make it blunt-ended, and ligated before being used to transform DH5 bacterial cells. Transformants were tested by PCR for the presence of plasmid with the deleted sequence that removed aa 34-128 (both inclusive) from the F2 chain of the F protein. In addition, residue 31 was changed from glutamic to aspartic acid as a consequence of the cloning strategy. The entire F segment of one of the plasmids (LF1-DF2) was sequenced and DF2 insert was subcloned into plasmid pRB21 (Blasco & Moss, 1995) after digestion with BamHI and EcoRI. This plasmid was used to select an rVV of the vRB12 strain by the method of Blasco and Moss (1995) . The rVV was plaque-purified three times and expression of F protein was tested by immunofluorescence with specific monoclonal antibody (mAb) 47F (García-Barreno et al., 1989) . rVV stocks were grown in CV-1 monolayers and consisted of clarified sonicated cell extracts purified by ultracentrifugation through a 36 % sucrose cushion. (Zhou et al., 1994) were provided by G. Hämmerling (German Cancer Research Centre, Heidelberg, Germany) and were cultured in RPMI 1640 medium supplemented with 10 % fetal bovine serum and 5610 25 M 2-mercaptoethanol. BALB/c fibroblast cells and human RSV Long persistently infected BCH4 fibroblast cells (Fernie et al., 1981) Polyclonal CTL lines and cytotoxicity assays. Female BALB/c mice (H-2 d haplotype) bred in our colony were infected by intraperitoneal injection of 10 7 p.f.u. of vvF or vvF-DF2. Three weeks post-infection an identical booster was given, and three or more weeks later mice were sacrificed and spleen cells obtained. CTL lines were named indicating the virus used for priming in vivo and the agent used for restimulation in vitro (Table 1) . Thus CTL F/RSV derive from vvF-primed mice and were restimulated in vitro with RSV-infected splenocytes, mimicking a described method (Gaddum et al., 1996) . Splenocytes from vvF-primed mice were stimulated with naïve splenocytes infected for 90 min with RSV Long at a m.o.i. of 0?4 p.f.u. per cell. Recombinant human interleukin 2 (IL2), generously provided by Hoffman-La Roche, was added 5 days later at 25 U ml 21 . Long-term cultures were restimulated weekly with IL2 and RSV-infected splenocytes at an effector : stimulator ratio of 3 : 1. The CTL F/BCH4 and CTL DF2/BCH4 lines were generated by stimulating 5610 6 splenocytes ml 21 with 2610 5 BCH4 cells ml 21 treated with 90 mg mitomycin C ml 21 (Sigma). IL2 (25 U ml 21 ) was added after 5 days. Long-term cultures were restimulated weekly with IL2 and mitomycin C-treated splenocytes and BCH4 cells at an effector : stimulator ratio of 3 : 1 and 5 : 1, respectively. The CTL F/F85-93 and CTL F/F249-257 lines were generated by stimulating 10 7 splenocytes ml 21 with 10 210 M of the relevant peptide. Five days after selection, IL2 (25 U ml 21 ) was added. Long-term cultures were maintained by weekly restimulation with mitomycin C-treated 10 26 M peptide-pulsed splenocytes (effector : stimulator ratio of 3 : 1) and cultured in medium with IL2 and 10 210 M peptide. All CTL lines were cultured in minimal essential medium a supplemented with 10 % inactivated fetal bovine serum and 5610 25 M 2-mercaptoethanol at 37 uC in a 5 % CO 2 atmosphere. Standard 3-4 h 51 Cr release cytotoxicity assays (Del Val et al., 1988) were performed incubating CTL and target cells that had been previously labelled for 60-90 min with Na 51 CrO 4 at 37 uC in the presence or absence of 10 26 M peptide and washed. Down to 100-fold lower peptide concentrations gave similar results. Alternatively, P13.1 cells were infected with rVV at a m.o.i. of 3-10 p.f.u. per cell as described (Eisenlohr et al., 1992) , virus inoculum was thoroughly washed after 1 h adsorption, and infection was allowed to proceed for 3 h prior to cytotoxicity assay.
Intracellular cytokine staining. Intracellular cytokine staining assays were performed as described previously (Chen et al., 2000) . CTL lines were stimulated in the presence of 10 mg brefeldin A ml
21
(Sigma) for 4 h with P13.1 target cells previously pulsed for 30 min with an excess 10 25 M peptide. Pooled splenocytes were stimulated with an excess 10 25 M peptide for up to 2 h, and stimulated for a further 3 h in the presence of brefeldin A. Following stimulation, cells were incubated with FITC-conjugated anti-CD8a (clone 53-6.7) mAb for 20 min at 4 uC, fixed with Intrastain kit (DakoCytomation) reagent A, and incubated with phycoerythrin-conjugated mAb to interferon-c (IFN-c) in the presence of Intrastain kit permeabilizing reagent B for 30 min at 4 uC. All antibodies were purchased from BD PharMingen. Events were acquired using a FACSCalibur flow cytometer (BD Biosciences) and data were analysed using CellQuest software (BD Biosciences).
RESULTS AND DISCUSSION
In vitro generated CTL lines specific for the F glycoprotein of the Long strain of RSV identify F85-93 as a conserved epitope Polyclonal F-specific CTL lines were generated in vitro from splenocytes obtained from BALB/c mice primed with vvF, an rVV encoding wild-type fusion glycoprotein F of RSV Long. Initially, polyclonal CTL lines were generated using procedures that kept them multispecific, that is, capable of recognizing as many F glycoprotein epitopes as possible. Thus, the CTL F/RSV line was generated by in vitro restimulation with RSV Long-infected splenocytes (Gaddum et al., 1996) . Using a novel approach the CTL F/BCH4 line was generated by stimulation with BCH4 cells. RSV Long persistently infected BCH4 cells (Fernie et al., 1981) have been extensively used as targets of F-specific CTL despite their reduced synthesis of F and G viral glycoproteins (Martínez et al., 2001 ). However, they have not been previously used as stimulators to obtain F-specific CTL lines. Functional characterization of CTL lines was carried out in cytotoxicity assays with 51 Cr-labelled BCH4 cells as RSV-infected targets (Fig. 1a) . Both CTL F/RSV and CTL F/BCH4 lines were able to recognize RSV persistently infected BCH4 targets, whereas no significant lysis was observed with non-infected P13.1 targets. Poorer performance of CTL F/RSV might reveal a suboptimal restimulation protocol. BALB/c fibroblasts (Fernie et al., 1981) were not used as a negative control as, unexpectedly, no evidence was found of presentation of any synthetic peptide representing known viral epitopes to proven active CTL. Lack of recognition of wild-type vaccinia-infected cells confirmed the absence of vaccinia-specific CTL in CTL F/BCH4 that were otherwise able to efficiently detect presentation of F protein epitopes in vvF-infected cells (Fig. 1b) .
F glycoprotein epitopes in A2 strain of RSV are known to be presented only by MHC class I molecule K d (Chang et al., 2001) To identify epitopes presented by K d to multispecific CTL F/RSV and CTL F/BCH4, we first assessed in cytotoxicity assays whether protein epitopes known in the A2 strain were recognized. Peptides F85-93 and F92-106 corresponding to these epitopes were synthesized and used to sensitize cells. We found that peptide F92-106 is not recognized by either CTL line (Fig. 1c) and also fails to restimulate F-primed CTL (data not shown). Despite 98 % aa identity between the F glycoproteins of RSV strains A2 and Long (Ló pez et al., 1988) , residues 11 and 12 of this 15-mer F92-106 epitope are not conserved (PT in A2 and AA in Long) and may be critical for the unpredictable non-canonical binding of the epitope to K d . It cannot be excluded either that the F92-106 peptide is not a good reagent to mimic this potential epitope in the Long strain. Therefore, in RSV Long we have no evidence of the presence of this epitope.
On the other hand, both multispecific CTL F/RSV and CTL F/BCH4 lines were able to recognize F85-93 sensitized cells (Fig. 1c) . Furthermore, a long-term polyclonal monospecific CTL F/F85-93 line was generated by stimulating splenocytes from vvF-primed mice with F85-93 peptide. Titration assays were performed by pulsing targets with increasing concentrations of peptide, and both multispecific CTL F/BCH4 and monospecific CTL F/F85-93 were found to recognize down to 10 211 M F85-93 (Fig. 1d) . Therefore, as expected from the conserved sequence within the epitope and flanking regions, F85-93 is also a CTL epitope in the Long strain.
Identification of CTL epitope F249-258 in the F glycoprotein of the Long strain of RSV To identify other potential CTL epitopes in the F glycoprotein of the Long strain we constructed an rVV, vvF-DF2, encoding a mutant F protein in which aa 34-128 have been deleted, and which therefore does not contain the F85-93 epitope. Although the mutant was constructed in such a way as to allow maturation of the full F1 chain, reduced levels of expression compared with the wild-type protein were detected (data not shown). In spite of the lower expression of the mutant protein, cells infected with vvF-DF2 were efficiently lysed by CTL F/BCH4, thus demonstrating presentation of one or more undefined epitopes from vvF-DF2-infected cells to multispecific CTL F/BCH4 (Fig. 2a) . It can be argued that a F85-93 mimotope may be recognized by F85-93-specific CTL clones present in the multispecific CTL line, or that an artificial epitope is being generated from the mutant protein. To address this issue the same targets were assayed with monospecific CTL F/F85-93 and no lysis was observed (Fig. 2a) . Furthermore, a multispecific CTL DF2/BCH4 line that did not include F85-93-specific clones was generated from mice that had been primed with vvF-DF2 (see Table 1 ). Cytotoxicity assays were performed and as expected CTL DF2/BCH4 were unable to lyse targets exogenously loaded with F85-93, but were, however, able to recognize vvF-infected targets (Fig. 2b ). We therefore demonstrate the existence of one or more novel uncharacterized RSV Long F glycoprotein epitopes in the F1 chain or in the first 33 aa of the protein.
In order to identify the novel epitope or epitopes, RSV Long F protein sequence was subjected to MHC class I epitope prediction programs based on motif-refined algorithms, excluding prediction of non-canonical epitopes. Programs used were SYFPEITHI (Rammensee et al., 1999) and BIMAS (Parker et al., 1994) . High-score putative epitopes predicted to be presented by K d with both programs were further screened for correct C-terminal proteasomal cleavage in NetChop 2.0 Prediction Server (Keşmir et al., 2002) , and peptides corresponding to several predicted epitopes were synthesized. In some instances, length variants of the same region with similar scores were synthesized. We established our internal threshold by subjecting known viral K d -restricted epitopes to each epitope prediction program. Presentation of peptides to CTL F/BCH4 was assessed in cytotoxicity assays performed with peptide-pulsed T2/K d targets, which are deficient in transporters associated with antigen processing and thus have more peptide-receptive molecules available. Fig. 3(a) shows that targets pulsed with peptides F249-257 and F249-258 were efficiently lysed by CTL, as were F85-93 peptide-pulsed targets. Again, to control that F249-257/8 peptides were not being crossrecognized by F85-93-specific CTL clones, the same targets were confronted to CTL F/F85-93, but these were only able to recognize the F85-93 peptide (Fig. 3a, second  panel) . Moreover, to address the possibility of a nonspecific binding to other human presenting molecules expressed by T2 targets, an assay was performed with CTL F/BCH4 and peptide-pulsed T2/L d targets and no specific lysis was observed (Fig. 3a, third panel) . These results indicate that peptides F249-257 and F249-258 are presented by K d to specific CTL clones. As it may be argued that targets are pulsed with high concentrations of peptide (10 26 M), titration assays were performed to assess whether physiological concentrations of the peptides were recognized. Fig. 3(b) shows that targets pulsed with down to 10 210 M peptide were efficiently lysed and that the 9-and 10-mer peptides were equally recognized by CTL F/BCH4. Reciprocal CTL lysis may account for the reduced lysis observed at high peptide concentrations. Altogether, these results demonstrate that standard concentrations of the F249-257 and F249-258 peptides can specifically activate RSV Long F protein-specific CTL.
Furthermore, a polyclonal monospecific CTL F/F249-257 line was generated from vvF-primed mice by stimulating splenocytes with F249-257 synthetic peptide. The CTL F/F249-257 line was able to recognize targets pulsed with down to 10 211 M peptide (Fig. 4a) , and to efficiently lyse vvF and vvF-DF2-infected targets (Fig. 4b) . For the establishment of this CTL line, different F249-257 peptide concentrations were tested in restimulation. The optimal concentration, 10 210 M, was exactly the same as previously found optimal by us for CTL F/F85-93 (data not shown).
Importantly, this epitope was also generated in natural RSV infection of mice, as similar polyclonal monospecific CTL RSV/F249-258 could be established (data not shown).
In contrast, neither recognition of peptide-pulsed target cells nor generation of monospecific CTL lines were observed with other predicted epitope peptides (F365-373 and F467-475, data not shown). The possibility cannot be excluded that other epitopes may exist within the deleted region, but a further predicted epitope located in the region deleted in vvF-DF2 represented by synthetic peptides F31-40 and F32-40 was also tested and found negative (data not shown). The results are summarized in Fig. 5 . Thus, we have identified a CTL epitope that is presented by K d as a 9-mer (F249-257; TYMLTNSEL) or a 10-mer (F249-258; TYMLTNSELL) peptide. This epitope is located near neutralizing antibody antigenic site II , and is expected to also exist in the F protein of the A2 strain as its sequence and that of the flanking regions that may influence the efficiency of antigen processing and presentation (Del Val et al., 1991) are also conserved in at least 35 residues on either side. However, this F249-257/8 epitope has not been identified in previous studies (Chang et al., 2001; Jiang et al., 2002 ) that used overlapping peptides in their screening. The panel of 15-mer overlapping peptides used in the identification of non-canonical A2 strain F92-106 epitope did not include any peptide in which the F249-257/8 epitope was complete (Jiang et al., 2002) , which explains why it was not detected. Our results demonstrate that epitope prediction programs, although unable to predict non-canonical epitopes, can be powerful tools for CTL epitope identification, as discussed recently (Nussbaum et al., 2003) .
Shifting immunodominance pattern of CD8 + Tlymphocyte responses to F85-93 and F249-258 after in vivo vvF infection and in CTL lines
A potential competition between the two epitopes presented by K d and located in the F protein of RSV Long (F85-93 and F249-257/8) led us to examine the hierarchy of CD8 + T-lymphocyte responses. Factors that potentially contribute to immunodominance include efficiency of antigen processing, binding affinity of peptides to class I molecules, presence of T lymphocytes capable of responding to a given peptide/MHC complex and inhibition of responses to subdominant epitopes by CD8 + T lymphocytes specific for dominant epitopes (Chen et al., 2000; Yewdell & Bennink, 1999) . The fact that recognition of peptide F249-257 by monospecific CTL F/F249-257 was better than by CTL F/BCH4 (Figs 4a and 3b, respectively) , suggested that F249-257 might be a subdominant determinant in the latter multispecific CTL line. Furthermore, when T lymphocyte clones specific for the immunodominant F85-93 epitope were not present in the CTL line, as in CTL DF2/ BCH4 or in CTL F/F249-257 (see Table 1 ), targets pulsed with down to 10 211 M F249-257 peptide were efficiently lysed (Fig. 6a) . Therefore, the limit in F249-257 peptide recognition by CTL F/BCH4 is imposed by F85-93-specific T lymphocyte clones, not by BCH4 cells, as these are able to select more sensitive CTL when stimulating splenocytes from vvF-DF2-primed mice.
Further evidence of the decreased sensitivity in epitope recognition of F249-257/8-specific CTL clones present in CTL F/BCH4 came from the different recognition pattern observed at low effector to target (E : T) ratios in a cytotoxicity assay performed with multispecific CTL F/BCH4 and infected targets (Fig. 6b) . At an E : T ratio of 1 : 1, 50 % or more specific lysis was only reached with targets presenting the F85-93 immunodominant epitope, with both peptide-pulsed and vvF-infected cells. Differences in recognition did not result from differences in efficiency of antigen presentation from vvF and vvF-DF2, as Fig. 4(b) shows that both rVV were able to equally present the subdominant determinant to CTL F/F249-257, a CTL line devoid of F85-93-specific T lymphocyte clonotypes. In fact, recognition of vvF by CTL F/BCH4 (Fig. 6b) is higher than by CTL F/F249-257 (Fig. 4b) . This is not unexpected, as recognition of more epitopes by the former multispecific line than by the latter monospecific line (see Table 1 ) can easily account for this. increasing concentrations of peptide F249-257, and a titration cytotoxicity assay was performed at a 5 : 1 E : T ratio using CTL DF2/BCH4 (n), CTL F/F249-257 ($) and multispecific CTL F/BCH4 (%) as effectors (see Table 1 To assess whether responses to the immunodominant determinant F85-93 were preventing the emergence of responses to the subdominant determinant F249-257/8, we quantified CD8 + T lymphocytes specific for each epitope in an intracellular cytokine staining assay using peptidepulsed cells to stimulate CTL F/BCH4 and CTL DF2/BCH4. Fig. 7(a) (upper panels) shows that when targets were pulsed with peptide F85-93, 77 % of the CD8 + lymphocytes in the CTL F/BCH4 line were activated to produce IFN-c, whereas only 9?8 and 9?4 % of the CD8 + lymphocytes were activated by peptides F249-257 and F249-258, respectively. Therefore CTL lines obtained from vvF-primed memory mice show immunodominance, as CTL responses are strongly skewed to F85-93 at the expense of responses to F249-257/8. Interestingly, when the immunodominant epitope F85-93 was absent in the in vivo priming event that led to the generation of the CTL DF2/BCH4 line, 98 and 52 % activation was achieved by stimulation with peptides F249-258 and F249-257, respectively, showing that in the absence of the F85-93 epitope, responses to the F249-257/8 epitope are very efficiently generated. Thus, there is no limitation in the in vivo availability of CD8 + T lymphocytes capable of responding to F249-257/8.
In addition, as 98 % of CD8 + T lymphocytes in CTL DF2/ BCH4 responded to F249-258 10-mer peptide, we suggest that no other epitope is recognized by this CTL line. Concerning endogenous antigen processing of the F glycoprotein in BCH4 cells, the fact that 10-mer F249-258 is recognized by all CTL in the CTL DF2/BCH4 line strongly suggests that the 10-mer is probably a naturally produced K d ligand in BCH4 cells.
Hierarchy in primary, memory and secondary CD8 + Tlymphocyte responses to F85-93, F249-257 and F249-258 was studied in vivo after vvF infection (Fig. 7b) . CD8 + lymphocytes activated with each peptide in an intracellular cytokine staining assay are observed with a frequency similar to that reported in other systems (Chen et al., 2000) . Staining with tetramers K d /F85-93 and K d /F249-258 essentially gave the same results (data not shown). Low frequencies are probably due to competition with vaccinia virus determinants, which for example have previously been suggested to account for difficulty in detection of the NP 147-155 epitope following infection with an rVV encoding the complete influenza virus nucleoprotein, NP (Chen et al., 2000; Restifo et al., 1995) . This has been discussed in terms with 10 7 p.f.u. vvF to study the primary response (white bars; data are the mean of seven mice from four independent experiments). The memory response was assessed in mice that received a booster of vvF 3 weeks later, and then were left resting for several months (grey bars; data are the mean of two mice from two independent experiments). The secondary response was studied in animals of the memory response group 7 days after a third dose of vvF (black bars; data are the mean of two mice from two independent experiments). Percentage of total CD8 + lymphocytes that stained for IFN-c after activation with each peptide is represented. A mean of 50 000 CD8 + cells were analysed in each sample.
of the limitations of viral vectors that elicit massive CTL responses to their own antigens.
In the primary immune response to vvF (Fig. 7b , white bars), there is no limitation for the generation of a similarly effective CD8 + T-lymphocyte response to either epitope, as frequencies are comparable after stimulation with either peptide, thus concluding that no significant hierarchy exists in the in vivo primary response in vvF-infected mice. However, frequencies of epitope-specific populations in the memory immune response (Fig. 7b, grey bars) increase for F85-93 and decrease for F249-257/8 in comparison with the primary immune response (Fig. 7b, white bars) . Therefore, in the initial experimental setting for in vitro selection of CTL lines by restimulation with BCH4 cells, the F85-93-specific CD8
+ T lymphocyte population is already in advantage. This difference is probably amplified by restimulation with BCH4 cells to that observed in the CTL F/BCH4 line (Fig. 7a) .
Furthermore, in a secondary immune response (Fig. 7b , black bars) the mean percentage of activated CD8
+ lymphocytes after stimulation with peptide F85-93 is almost 10-fold higher than after stimulation with peptides F249-257 or F249-258. This difference in the number of F85-93 and F249-257/8 epitope-specific CD8 + T lymphocytes is similar in proportion to that observed in the established in vitro generated CTL F/BCH4 line (Fig. 7a) . Therefore, the CTL F/BCH4 line is representative of an in vivo secondary response to vvF infection.
Different patterns of T cell immunodominance in primary and secondary responses have been described previously (Belz et al., 2000; Crowe et al., 2003) (Belz et al., 2000) . The mechanism underlying this changing pattern of immunodominance has been investigated in a recent study that proposes a model in which differential antigen presentation by dendritic and non-dendritic cells together with the capacity of T cells to perceive the antigens presented by these cells, regulate the T cell specificity pattern (Crowe et al., 2003) . Along with this hypothesis, we suggest that in our experimental system professional antigen presenting cells with a similar proportion of epitopes F85-93 and F249-258 would activate naïve T cells during the primary immune response, whereas during the secondary immune response memory T cells would also be activated by cross-priming or by nonprofessional antigen presenting cells with a higher proportion of epitope F85-93. This would lead to the gradual establishment of a CD8 + T-lymphocyte response strongly skewed to epitope F85-93.
The different immunodominance pattern for epitopes F85-93 and F249-258 observed in primary and secondary vvF infection must be taken into account when considering single epitope vaccines. However, the finding that CD8 + T lymphocytes specific for either epitope are generated in vivo holds promise for the potential to generate a multispecific CD8 + response in natural infection or after vaccination. In conjunction with neutralizing antibodies targeting the F protein, a multispecific CD8 + response would better contribute to clearing RSV infection, as it would hinder the emergence of viral CTL escape mutants lacking single determinants. Definition of novel CTL epitopes thus contributes to addressing these issues in the mouse model.
